Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia

Francesco Fazi, Giuseppe Zardo, Vania Gelmetti, Lorena Travaglini, Alberto Ciolfi, Luciano Di Croce, Alessandro Rosa, Irene Bozzoni, Francesco Grignani, Francesco Lo-Coco, Pier Giuseppe Pelicci, Clara Nervi

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis.

Original languageEnglish
Pages (from-to)4432-4440
Number of pages9
JournalBlood
Volume109
Issue number10
DOIs
Publication statusPublished - May 15 2007

Fingerprint

Tretinoin
Acute Myeloid Leukemia
Genes
Epigenetic Repression
Acid resistance
Myelopoiesis
Azacitidine
Retinoic Acid Receptors
Histone Deacetylases
Nucleic Acid Regulatory Sequences
DNA
Hematopoiesis
Methyltransferases
DNA Methylation
Epigenomics
Small Interfering RNA
Chromatin
Conformations
Leukemia
Fusion reactions

ASJC Scopus subject areas

  • Hematology

Cite this

Fazi, F., Zardo, G., Gelmetti, V., Travaglini, L., Ciolfi, A., Di Croce, L., ... Nervi, C. (2007). Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood, 109(10), 4432-4440. https://doi.org/10.1182/blood-2006-09-045781

Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. / Fazi, Francesco; Zardo, Giuseppe; Gelmetti, Vania; Travaglini, Lorena; Ciolfi, Alberto; Di Croce, Luciano; Rosa, Alessandro; Bozzoni, Irene; Grignani, Francesco; Lo-Coco, Francesco; Pelicci, Pier Giuseppe; Nervi, Clara.

In: Blood, Vol. 109, No. 10, 15.05.2007, p. 4432-4440.

Research output: Contribution to journalArticle

Fazi, F, Zardo, G, Gelmetti, V, Travaglini, L, Ciolfi, A, Di Croce, L, Rosa, A, Bozzoni, I, Grignani, F, Lo-Coco, F, Pelicci, PG & Nervi, C 2007, 'Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia', Blood, vol. 109, no. 10, pp. 4432-4440. https://doi.org/10.1182/blood-2006-09-045781
Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood. 2007 May 15;109(10):4432-4440. https://doi.org/10.1182/blood-2006-09-045781
Fazi, Francesco ; Zardo, Giuseppe ; Gelmetti, Vania ; Travaglini, Lorena ; Ciolfi, Alberto ; Di Croce, Luciano ; Rosa, Alessandro ; Bozzoni, Irene ; Grignani, Francesco ; Lo-Coco, Francesco ; Pelicci, Pier Giuseppe ; Nervi, Clara. / Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. In: Blood. 2007 ; Vol. 109, No. 10. pp. 4432-4440.
@article{e78883ba37914378ba582f83f43d705b,
title = "Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia",
abstract = "Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis.",
author = "Francesco Fazi and Giuseppe Zardo and Vania Gelmetti and Lorena Travaglini and Alberto Ciolfi and {Di Croce}, Luciano and Alessandro Rosa and Irene Bozzoni and Francesco Grignani and Francesco Lo-Coco and Pelicci, {Pier Giuseppe} and Clara Nervi",
year = "2007",
month = "5",
day = "15",
doi = "10.1182/blood-2006-09-045781",
language = "English",
volume = "109",
pages = "4432--4440",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia

AU - Fazi, Francesco

AU - Zardo, Giuseppe

AU - Gelmetti, Vania

AU - Travaglini, Lorena

AU - Ciolfi, Alberto

AU - Di Croce, Luciano

AU - Rosa, Alessandro

AU - Bozzoni, Irene

AU - Grignani, Francesco

AU - Lo-Coco, Francesco

AU - Pelicci, Pier Giuseppe

AU - Nervi, Clara

PY - 2007/5/15

Y1 - 2007/5/15

N2 - Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis.

AB - Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis.

UR - http://www.scopus.com/inward/record.url?scp=34248356405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248356405&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-09-045781

DO - 10.1182/blood-2006-09-045781

M3 - Article

C2 - 17244680

AN - SCOPUS:34248356405

VL - 109

SP - 4432

EP - 4440

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -